Scarica l'app Stockscreener
0.6946
2.00%
0.0136
Dopo l'orario di chiusura:
.68
-0.0146
-2.10%
Tenaya Therapeutics Inc Borsa (TNYA) Ultime notizie
William Blair analysts confident on Tenaya Therapeutics (TNYA) product pipeline - MSN
TNYA Technical Analysis | Trend, Signals & Chart Patterns | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
TNYA pulls back after hours following significant $1.13B deal-spurred rally - msn.com
Pullback Watch: Is Tenaya Therapeutics Inc part of any ETF2026 Levels & Daily Profit Focused Stock Screening - baoquankhu1.vn
symbol__ Stock Quote Price and Forecast - CNN
Tenaya Therapeutics (TNYA) price target increased by 11.11% to 10.20 - msn.com
TNYA Stock Price, Quote & Chart | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
William Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product Pipeline - Yahoo Finance
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - MSN
Tenaya Therapeutics, Inc. (TNYA) reports Q4 EPS of (12c), in line with consensus - MSN
Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus - Insider Monkey
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
How TN-301 Progress And Alnylam Deal At Tenaya Therapeutics (TNYA) Has Changed Its Investment Story - simplywall.st
Tenaya Therapeutics (NASDAQ:TNYA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
What is Lifesci Capital's Estimate for TNYA Q1 Earnings? - MarketBeat
Outperform Maintained on Tenaya Therapeutics (TNYA) by Leerink and William Blair March 2026 - Meyka
Tenaya Therapeutics (TNYA) Valuation After TN-301 Data And New Alnylam Collaboration - simplywall.st
William Blair reiterates Outperform on Tenaya Therapeutics stock By Investing.com - Investing.com Australia
Leerink Partners reiterates Outperform on Tenaya stock at $2 - Investing.com UK
William Blair reiterates Outperform on Tenaya Therapeutics stock - Investing.com
Chardan Capital Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA) - MarketBeat
Tenaya Therapeutics Reports Promising 2025 Results, Advances Gene Therapy Programs, and Extends Cash Runway Into 2027 - Minichart
Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal - Yahoo Finance
Tenaya Therapeutics: Advancing Genetic Medicines and Small Molecule Therapies for Heart Disease Treatment - Minichart
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
Tenaya Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027 - TradingView
Tenaya Therapeutics (NASDAQ:TNYA) Issues Earnings Results, Meets Expectations - MarketBeat
Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
TNYA: Clinical progress, Alnylam deal, and financing extend cash runway into 2027 - TradingView
Tenaya Therapeutics (NASDAQ: TNYA) narrows 2025 loss and extends cash runway to 2027 - Stock Titan
Q4 and 2025 results drive business momentum, Tenaya Therapeutics outlines - Traders Union
BRIEF-Tenaya Therapeutics Q4 Net Income USD -20.175 Million Vs. IBES Estimate USD -22 Million - TradingView
Heart gene therapy data and $1.1B Alnylam deal help Tenaya fund work to 2027 - Stock Titan
Tenaya Therapeutics Soars with Major Collaboration Deal - timothysykes.com
Tenaya Therapeutics Reports TN-301 Outperforms Givinostat in Enhancing Muscle Function and Addressing DMD Cardiomyopathy - Quiver Quantitative
Experimental drug TN-301 restores muscle strength in Duchenne mice - Stock Titan
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):